Phase 2 trial of pembrolizumab plus SurVaxM for patients with glioblastoma at first recurrence (RESURGe)

Manmeet Ahluwalia, Miami Cancer Institute
Ahmad Ozair, Baptist Health South Florida

Abstract

This paper has been withdrawn.